Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.
from @ Health and Medical News http://ift.tt/1F2oxcC
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
from @ Health and Medical News http://ift.tt/1F2oxcC
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
